NCT06258031View on ClinicalTrials.gov

PsilOCD: A Pharmacological-Challenge Feasibility Study

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

June 28, 2024

Study Completion Date

July 24, 2024

Conditions

Obsessive-Compulsive Disorder

Interventions

DRUG

Psilocybin (COMP360)

Up to 10mg on two occasions

Trial Locations (1)

W10 6DZ

CIPPRes Clinic, London

All Listed Sponsors

lead

Imperial College London

OTHER